29 Nov 2013 Calon to present technical update at 8th EUMS

Calon is pleased to announce that its CTO Dr Graham Foster, will present an update on the Calon MiniVAD development programme at the forthcoming EUMS meeting in Paris. The session will include on update on progress through the in-vivo elements of the development project and outline in vitro results obtained using the company's novel and proprietary assays for blood damage, funded through the recently awarded Technology Strategy Board grant.

Simon Cartmell, CEO, commented "it is important for us to keep the clinical community abreast of our progress given the interest shown in the MiniVAD by VAD specialists. The EUMS meeting is a fantastic gathering of thought leaders in the field and is an ideal opportunity to do so, especially as we contemplate the clinical components of the development programme."

For more information contact Graham Foster, Chief Technology Officer, on +44 (0)1792 602811



Disclaimer: Calon Cardio’s VAD devices are not available for sale, including in the United States of America